| PRECLINICAL | evidence | Case Report: Small Bowel Obstruction After Starting Tirzepatide (Mounjaro). | Mounjaro | — | 2024-12-01 |
| PRECLINICAL | evidence | Acute Pancreatitis Caused by Tirzepatide. | Mounjaro | — | 2024-12-01 |
| PRECLINICAL | evidence | Investigating GLP-1 Injections: Potential Mitochondrial Dysfunction in Non-Diabetic Patients Presenting with Migraines and Hypoglycemia: A Case Report. | Mounjaro | — | 2024-12-01 |
| PRECLINICAL | evidence | A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point? | Mounjaro | Weight & fat loss | 2024-11-01 |
| PRECLINICAL | evidence | Population-Level Interest in Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Using Google Trends Statistics in a 12-Month Retrospective Analysis: An Infodemiology and Infoveillance Study. | Mounjaro | — | 2024-10-01 |
| PRECLINICAL | evidence | Update on Perioperative Medication Management for the Hand Surgeon: A Focus on Diabetes, Weight Loss, Rheumatologic, and Antithrombotic Medications. | Mounjaro | — | 2024-10-01 |
| PRECLINICAL | evidence | Table: GLP-1 and GIP/GLP-1 receptor agonists for chronic weight management. | Zepbound | Weight & fat loss | 2024-08-05 |
| PRECLINICAL | evidence | Table: GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes. | Mounjaro | Glycemic control | 2024-08-05 |
| PRECLINICAL | evidence | Tirzepatide (Zepbound) for the Treatment of Obesity. | Zepbound | Weight & fat loss | 2024-08-01 |
| PRECLINICAL | evidence | The association between weight loss medications and cardiovascular complications. | Mounjaro | — | 2024-07-01 |
| PRECLINICAL | evidence | A mathematical model of obesity-induced type 2 diabetes and efficacy of anti-diabetic weight reducing drug. | Mounjaro | Glycemic control | 2024-03-21 |
| PRECLINICAL | evidence | Tirzepatide: A Review in Type 2 Diabetes. | Mounjaro | Glycemic control | 2024-02-01 |
| PRECLINICAL | evidence | Injectable Weight Loss Medications in Plastic Surgery: What We Know, Perioperative Considerations, and Recommendations for the Future. | Mounjaro | — | 2024-01-01 |
| PRECLINICAL | evidence | A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide. | Mounjaro | — | 2024-01-01 |
| PRECLINICAL | evidence | Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. | Mounjaro | Weight & fat loss | 2024-01-01 |
| PRECLINICAL | evidence | Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study. | Mounjaro | Weight & fat loss | 2024-01-01 |
| PRECLINICAL | evidence | Tirzepatide (Zepbound) for chronic weight management. | Mounjaro | Glycemic control | 2023-12-25 |
| PRECLINICAL | evidence | FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management. | Zepbound | Weight & fat loss | 2023-12-12 |
| PRECLINICAL | evidence | Tirzepatide for type 2 diabetes. | Mounjaro | — | 2023-12-01 |
| PRECLINICAL | evidence | In brief: GI effects of GLP-1 receptor agonists. | Mounjaro | Glycemic control | 2023-11-27 |
| PRECLINICAL | evidence | A narrative review of approved and emerging anti-obesity medications. | Mounjaro | — | 2023-10-01 |
| PRECLINICAL | evidence | Current findings on the efficacy of incretin-based drugs for diabetic kidney disease: A narrative review. | Mounjaro | Glycemic control | 2023-09-01 |
| PRECLINICAL | evidence | Comparing Efficacy and Safety of Different Doses of Tirzepatide for the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. | LY3298176 | — | 2023-08-01 |
| PRECLINICAL | evidence | Tirzepatide (Mounjaro) for the Treatment of Type 2 Diabetes Mellitus. | Mounjaro | Glycemic control | 2023-07-01 |
| PRECLINICAL | evidence | Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity. | Mounjaro | Glycemic control | 2023-05-01 |
| PRECLINICAL | evidence | Adverse Events Related to Tirzepatide. | LY3298176 | — | 2023-02-09 |
| PRECLINICAL | evidence | New Drug: Tirzepatide (Mounjaro()). | Mounjaro | — | 2023-02-01 |
| PRECLINICAL | evidence | Tirzepatide: A New Generation Therapeutic for Diabetes Type 2. | Mounjaro | Glycemic control | 2023-01-01 |
| PRECLINICAL | evidence | Enteroendocrine cell regulation of the gut-brain axis. | Mounjaro | — | 2023-01-01 |
| PRECLINICAL | evidence | Tirzepatide: A Systematic Update. | LY3298176 | Glycemic control | 2022-11-23 |
| PRECLINICAL | evidence | Drugs for type 2 diabetes. | Mounjaro | Glycemic control | 2022-11-14 |
| PRECLINICAL | evidence | Tirzepatide-Friend or Foe in Diabetic Cancer Patients? | LY3298176 | — | 2022-10-28 |
| PRECLINICAL | evidence | A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. | LY3298176 | Glycemic control | 2022-08-01 |
| PRECLINICAL | evidence | Tirzepatide (Mounjaro) for type 2 diabetes. | Mounjaro | Glycemic control | 2022-07-11 |
| PRECLINICAL | evidence | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. | Mounjaro | Glycemic control | 2022-07-05 |
| PRECLINICAL | evidence | Tirzepatide: First Approval. | Mounjaro | — | 2022-07-01 |
| PRECLINICAL | evidence | Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors. | LY3298176 | Glycemic control | 2022-06-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials. | LY3298176 | — | 2021-09-28 |
| PRECLINICAL | evidence | Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. | LY3298176 | Glycemic control | 2020-11-01 |
| PRECLINICAL | evidence | Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. | LY3298176 | Gut barrier & GI healing · preclinical | 2020-07-01 |
| PRECLINICAL | evidence | How May GIP Enhance the Therapeutic Efficacy of GLP-1? | LY3298176 | Glycemic control | 2020-06-01 |
| PRECLINICAL | evidence | Tirzepatide. | Mounjaro | — | 2006-01-01 |
| PRECLINICAL | evidence | Tirzepatida (Mounjaro(R), Zepbound(R)). | Mounjaro | — | 1994-01-01 |
| PRECLINICAL | evidence | Tirzepatide (Mounjaro(R), Zepbound(R)). | Mounjaro | — | 1994-01-01 |
| INDEPENDENT-REVIEW | review | Wanting to switch to zepbound after taking compounded tirzepatide
I was very hesitant to take a glp one and wanted to do it the "right way" . With a doctor etc. When I finally decided to do it my husband encouraged me to go through his friend who is a primary care doctor and has a side hustle weight loss clinic. He prescribed me compounded tirzepatide and hasn't really worked with me much since I | COMMUNITY | — | 2026-07-27 |
| INDEPENDENT-REVIEW | review | Anyone in Germany / EU interested in a Kang Labs group buy? SS-31, Epithalon (+ Tirzepatide / Retatrutide)
Hey guys,
is anyone here from Germany or elsewhere in the EU interested in doing a small group order from Kang Labs?
I’m mainly interested in trying SS-31 and Epithalon, but I don’t really need large amounts. Shipping is around $60, so I thought it could make sense to combine an order with | COMMUNITY | — | 2026-07-26 |
| INDEPENDENT-REVIEW | review | Tirzepatide has cured my anger and anxiety. What else can mimic those effects without the weight loss?
As the title says. I've always struggled with anxiety which ultimately manifests in extreme anger. Taking Tirzepatide has been a godsend, I no longer have the fog of anger all the time. It's been a huge help for me and ultimately everyone in my orbit.
I've lost the initial weight I wanted to | COMMUNITY | — | 2026-07-25 |
| INDEPENDENT-REVIEW | review | moving from tirzepatide to semaglutide..
Hey there, I will be moving to seoul in a week - as a student - and I am currently on semaglutide injections - prescribed by my endocrinologist in my country - a generic one tho - different brand - as it relatively cheaper than ozempic and i had zero side effects with it compared to ozempic or mounjaro - and it worked well for me - maybe because of | COMMUNITY | — | 2026-07-25 |
| INDEPENDENT-REVIEW | review | Semaglutide vs Tirzepatide
Hi I’m debating which one to go on. I was prescribed mounjaro (tirzepatide) by my physician but I don’t have insurance to cover it. I live in Canada and it would cost me over 300$. Whereas I can ask to be predicted Generic Ozempic (Semaglutide) which would be just over 100$/ month.
I’m in a pickle. Can I hear your experiences on either one! I’m 26, 5’1 156 pounds and | COMMUNITY | — | 2026-07-25 |
| INDEPENDENT-REVIEW | review | Questions on compound tirzepatide
[removed] | COMMUNITY | — | 2026-07-16 |